Updated Mar. 15, 2013 at 6:00 a.m.

Premium Lock Cornerstone's heart attack drug gets an FDA setback

Published: 2013-03-14 15:49:00
Updated: 2013-03-15 06:00:08

Heart research heart research Image 1 of 2 · Next Image…

Cornerstone disclosed that the Food and Drug Administration declined to approve the supplier of the active ingredient for Retavase, a heart attack drug the company acquired and expected to relaunch this year. The setback pushes launch plans to 2015....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2014 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Scroll